Potential effective treatment of refractory and relapsed AML

Chemotherapy for Relapsed AML: Making the Best Out of a Bad Situation

Current Clinical Trials

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with recurrent adult acute myeloid leukemia.

Look for Therapy

Pulmonary leukostasis in hyperleukocytotic AML is an oncologic emergency demanding rapid intervention. The combined treatment with chemotherapy and radiation appears useful.

Effective treatment of refractory and relapsed AML with the triple combination of mitoxantrone, topotecan and cytosin-arabinoside (MTC)

Patients (pts) with acute myeloid leukemia (AML) and mutant RAS benefit from high-dose cytarabine (HDAC) intensification: a Cancer and Leukemia Group B (CALGB) study

Studies of Voreloxin in AML  "We are extremely pleased by these interim results for both of our AML studies."

These data show that the combination of Mylotarg and Cytosar has significant activity with acceptable toxicities in children with relapsed AML.

Mylotarg®, Cytosar®, and Novantrone® Effective for Relapsed Adult AML (10/23/2008)

Mylotarg® May Decrease Relapse Rate in Patients with Newly Diagnosed AML (01/16/2007)

Mylotarg® and Vidaza® Effective for Elderly with AML or MDS (01/03/2007)

LOR-2040...including an advanced Phase II clinical trial with LOR-2040 and high dose Ara-C (HiDAC) in refractory and relapsed Acute Myeloid Leukemia (AML)

Nevertheless, within the limits discussed earlier, the cases described here illustrate that tyrosine kinase inhibition of c-kit and/or PDGFR using imatinib may have potential therapeutic use in AML.